Experience

MaxCyte, Inc.

• United States
• Biotechnology
• 1 - 100 Employee

• Senior Vice President | Global Marketing

  • Sep 2021 - Present

  At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions.



MBX Capital

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Venture Advisor

  • Sep 2020 - Present

  MBX is a venture capital partnership investing in good health, for everyone. At MBX, our investment team focuses on early-stage healthcare, medical device, and biotech companies. ◆ Advise and counsel on potential Life Science and Healthcare investment opportunities ◆ Seed through Series B investments in life sciences/healthcare startups MBX is a venture capital partnership investing in good health, for everyone. At MBX, our investment team focuses on early-stage healthcare, medical device, and biotech companies. ◆ Advise and counsel on potential Life Science and Healthcare investment opportunities ◆ Seed through Series B investments in life sciences/healthcare startups



Berkeley Lights

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President | Cell Therapy

  • Sep 2020 - Aug 2021

  The Opto™ Cell Therapy Development Workflow accelerates the creation of better therapeutics by enabling multiple functional assays to be performed simultaneously on 1000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link behavior to gene expression. The Opto™ Cell Therapy Development Workflow accelerates the creation of better therapeutics by enabling multiple functional assays to be performed simultaneously on 1000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link behavior to gene expression.



Thermo Fisher Scientific

• United States
• Biotechnology Research
• 700 & Above Employee

• Senior Director & General Manager | Cell and Gene Therapy

  • Oct 2019 - Sep 2020

  Bringing a cell or gene therapy to market is a monumental endeavor that requires commitment, dedication, and a lot of science. This work holds the potential to deliver life-changing treatments—Our mission is to help researchers succeed by providing high-quality materials, services, and support to help them translate their cell therapy from discovery to clinical research and commercial manufacturing.

• Director, Global Product Management

  • Jan 2018 - Nov 2019

  Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $24 billion and more than 70,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.Lead product management of the global fine chemicals business including the Alfa Aesar and Acros Organics brands of chemical products. Develop product strategy and manage innovation pipeline.



Minerva Biotechnologies

• United States
• Biotechnology
• 1 - 100 Employee

• Consultant / Business Development | Stem Cells & Cell Therapy

  • Jun 2016 - Jan 2018

  Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next-generation stem cell therapies. Both flow from Minerva’s fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1* ◆ Developed commercial strategy for the company's stem cell products ◆ Collaborated on development and IND filing for cell therapy (CAR-T) portfolio ◆ Established external partnerships and collaborations with industry thought leaders



Orig3n

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Business Officer | Stem Cells & Regenerative Medicine

  • Sep 2014 - Jun 2016

  ORIG3N develops novel approaches for drug efficacy screening and human healthcare utilizing Induced Pluripotent Stem Cells (iPSCs). We deliver products and services to the healthcare marketplace as well as technologies for biotechnology and pharmaceutical research and development. ◆ Responsible for ensuring the commercial success of ORIG3N's stem cell platform ◆ Developed and executed the organization's product, sales, and partnership strategies ◆ Part of founding leadership team that raised $15.6M in venture capital



Life Technologies

• United States
• Biotechnology Research
• 700 & Above Employee

• Associate Director, Product Management | Cell Biology

  • Feb 2014 - Sep 2014

  - Thermo Fisher Scientific Acquired Life Technologies in Feb 2014 - Thermo Fisher Scientific is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer.Lead product management of a $70M+ global cell biology portfolio including the industry leading Lipofectamine® brand of transfection reagents. Developed product strategy and managed innovation pipeline.◆ Reversed portfolio decline and drove portfolio to back-to-back quarters of double digit growth ◆ Launched Lipofectamine 3000 - exceeded global forecast and Awarded 2014 “Marketing Excellence: Impact Award"

• Sr. Product Manager | Primary & Stem Cell Systems

  • Mar 2011 - Feb 2014

  Life Technologies is a global biotechnology tools company dedicated to improving the human condition. The PSCS division provides innovative, biologically relevant systems that are representative of in vivo systems for major research and disease areas. Our products enable faster discovery and development of safer and more effective medicines.Lead product management for a portfolio of stem cell product including culture media and differentiation products. Responsible for alignment of strategies, resources and processes between Operations, R&D and Marketing functions◆ Developed and executed company's stem cell media strategy◆ Established collaborations with key opinion leaders in the stem cell space◆ Licensed and launched Essential 8 culture medium; exceeded revenue plan in ‘12 & ‘13◆ Launched products for the differentiation of pluripotent stem cells

• Product Manager | in vitro ADME/Tox

  • Sep 2008 - Mar 2011

  The ADME/Tox division provides innovative cell-based products and services to accelerate the development of safe, effective drugs and ensure the safety of all types of chemical compounds. Through internal research and collaboration, we work to extend the utility, reproducibility, viability and predictability of hepatic and other in vitro models.



Cogenics

• Biotechnology
• 1 - 100 Employee

• Senior Product Manager | Genotyping & Gene Expression

  • May 2006 - Sep 2008

  ► Senior Product Manager (March 2008 - September 2008) ► Product Manager (May 2006 - February 2008) Cogenics provides the broadest range of genomics services for both research and regulated projects, including services to support clinical trials, molecular diagnostics, pharmacogenomic discovery, validation, and biomarker research. Services include genotyping, sequencing, gene expression profiling, cell bank characterization, bioinformatics, DNA/RNA extraction, and biorepositories.



Synthonix Inc.

• United States
• Chemical Manufacturing
• 1 - 100 Employee

• Manager, Marketing & Business Development

  • Nov 2004 - May 2006

  Synthonix specializes in the synthesis of small molecule heterocycles designed with biological and pharmacological bias. Synthonix offers powerful molecules tailored to participate in proven chemical reactions such as Horner-Wadsworth-Emmons coupling, Suzuki and Stille coupling, condensations, cycloadditions, and many others. Synthonix specializes in the synthesis of small molecule heterocycles designed with biological and pharmacological bias. Synthonix offers powerful molecules tailored to participate in proven chemical reactions such as Horner-Wadsworth-Emmons coupling, Suzuki and Stille coupling, condensations, cycloadditions, and many others.



Sumitomo Corporation of Americas

• United States
• International Trade and Development
• 200 - 300 Employee

• Project Coordinator | Summit Pharmaceuticals

  • 2002 - 2004

  Summit Pharmaceuticals is a sourcing partner for major pharmaceutical corporations utilizing a global network of pharma experts and local market knowledge to offer the best solutions to save cost and time in drug development. Areas of expertise include sourcing of chemical intermediates, active pharmaceutical ingredients and development of new suppliers throughout the world for new chemicals. Summit Pharmaceuticals is a sourcing partner for major pharmaceutical corporations utilizing a global network of pharma experts and local market knowledge to offer the best solutions to save cost and time in drug development. Areas of expertise include sourcing of chemical intermediates, active pharmaceutical ingredients and development of new suppliers throughout the world for new chemicals.